BofA lowered the firm’s price target on Denali Therapeutics (DNLI) to $28 from $30 and keeps a Buy rating on the shares. The firm updated for Q4 results, cash and share count and increased its operating expense estimates in-line with recent trends.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics assumed with an Overweight at Morgan Stanley
- Denali Therapeutics: Promising Growth Prospects Despite Recent Setbacks
- Denali Therapeutics Discontinues DNL343 ALS Trial
- Denali Therapeutics discontinues active treatment extension in eIF2B Regimen G
- Denali Therapeutics price target lowered to $35 from $38 at B. Riley